Biodexa Pharmaceuticals Plc (BDRX) stock
Close on Nov 12, 2026Market cap $5.37MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- £4.02M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -139.15%
Fundamentals
- EPS, diluted
- -0.00 GBP
- Free cash flow
- -£5.59M
Trading
- Previous close
- $2.40
- Open
- $2.35
- Day's range
- $2.30 – $2.43
- Volume
- 16,360
- Average volume (20 days)
- 62,413
- Beta (5 years)
- 4.07
- RSI (14 days)
- 46.3
- Volatility (1 year)
- 2635.3%
- Relative volume
- 0.02×
- WACC
- 17.4%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BDRX | S&P 500 | Difference | BDRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +521.1% | -2.7% | +523.8 pts | ||
| 3 months | -80.2% | -1.7% | −78.4 pts | ||
| Year to date | -97.4% | +11.9% | −109.3 pts | ||
| 1 year | -98.9% | +12.0% | −110.9 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -95.4% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -96.1% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -87.4% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025, GBP
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Biodexa Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Biodexa Pharmaceuticals
Pharmaceutical Preparations
Biodexa Pharmaceuticals plc is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics. The company specializes in identifying, acquiring, and advancing clinical pharmaceutical assets, particularly targeting therapeutic indications with significant unmet medical needs. Its research and development initiatives encompass multiple proprietary pipeline programs, including MTX228 Tolimidone, MTX230 eRapa, and related investigational drug candidates. Through targeted clinical and laboratory efforts, the business directs its pipeline development toward advancing specialty treatment options.
Company profile, executives and historyBiodexa Pharmaceuticals stock: common questions
What is Biodexa Pharmaceuticals's stock price?
BDRX closed at $2.38 on Nov 12, 2026, down 0.83% on the day.
What is Biodexa Pharmaceuticals's market cap?
Biodexa Pharmaceuticals was worth $5.37M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BDRX's P/E ratio?
Biodexa Pharmaceuticals lost money over fiscal 2025 (diluted EPS -0.00 GBP), so it has no meaningful P/E ratio.
Does Biodexa Pharmaceuticals pay a dividend?
No. Biodexa Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has BDRX stock performed over the past year?
Including dividends, BDRX returned -98.9% over the past year, against +12.0% for the S&P 500.
Who are Biodexa Pharmaceuticals's competitors?
Companies most similar to Biodexa Pharmaceuticals by business, industry and size include BCYC, XTLB, MDCX, CDT, NCNA.
See a number that looks wrong?